AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo
retained text
Search fieldHome page Seeking Alpha - Power to InvestorsAbout PremiumCreate free accountSearch for Symbols, analysts, keywordsLog in AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo Jul 29, 2026, 4:14 AM ETAbbVie Inc. (ABBV) Stock, ABBV:CA StockBy : Arundhati Sarkar, SA News Editor AbbVie (ABBV) Wednesday said that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo, who are candidates for systemic therapy. With this approval, Rinvoq is now the first and To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below
document fetched 2026-07-29 08:29 · canonical https://seekingalpha.com/news/4620067-abbvie-wins-eu-clearance-for-rinvoq-as-first-systemic-treatment-for-non-segmental-vitiligo?feed_item_type=news